Will the Phase 2 trial "Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab" reach primary completion on or before Dec 31, 2029?

Resolves Yes if ClinicalTrials.gov record NCT07387198 (Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest) shows an actual primary completion date on or before Dec 31, 2029. Registered date at generation: Dec 31, 2029.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Dec 31, 2029, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.